Anavex披露拟在2026年年会上更新董事会并回应代理权争夺

false
0001314052
0001314052
2026-08-03
2026-08-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
August 3, 2026
ANAVEX
LIFE SCIENCES CORP.
(Exact
name of Registrant as Specified in Its Charter)
Nevada
001-37606
98-0608404
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
630
5th Avenue
,
20th Floor
New
York
,
NY
USA
10111
(Address of Principal
Executive Offices)
(Zip Code)
Registrant’s
Telephone Number, Including Area Code: 1-
844
-
689-3939
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common Stock, par value
$0.001 per share
AVXL
Nasdaq Stock Market LLC
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company
☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On August 3, 2026, Anavex Life Sciences Corp. (“Anavex” or
the “Company”) issued a press release announcing plans to refresh Anavex’s Board of Directors (the “Board”)
at its 2026 Annual Meeting of Stockholders(the “Press Release”). The Press Release includes an open letter to Anavex’s
stockholders responding to the preliminary proxy statement filed by PVG Asset Management Corporation and Patrick S. Adams, which seeks
to replace the entire Anavex Board.
A copy of the Press Release is furnished as Exhibit 99.1 to this Current
Report and is incorporated herein by reference.
The information included in this Item 7.01, including Exhibit 99.1, shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated August 3, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANAVEX LIFE SCIENCES CORP.
Date:
August 3, 2026
By:
/s/ Sandra Boenisch
Sandra Boenisch, CPA, CGA
Principal Financial Officer, Treasurer